New hope for acute schizophrenia: major global trial tests promising treatment
NCT ID NCT07105098
Summary
This study is testing whether an investigational medicine called NBI-1117568 can help reduce symptoms in adults with schizophrenia who need to be hospitalized. Researchers will compare the medicine against a placebo (inactive treatment) in 284 participants worldwide. The main goal is to see if the treatment improves schizophrenia symptoms over 5 weeks while participants stay in the hospital.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGCulver City, California, 90230, United States
-
Neurocrine Clinical Site
RECRUITINGGarden Grove, California, 92845, United States
-
Neurocrine Clinical Site
RECRUITINGRiverside, California, 92506, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30328, United States
-
Neurocrine Clinical Site
RECRUITINGNorth Canton, Ohio, 44720, United States
Conditions
Explore the condition pages connected to this study.